Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects

Pharmacological inhibitors of Bruton tyrosine kinase (BTK) have revolutionized treatment of B-lymphocyte malignancies and show great promise for dampening autoimmunity. The predominant BTK inhibitors tether irreversibly by covalently binding to cysteine 481 in the BTK catalytic domain. Substitution...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Estupiñán, H. Yesid, Bouderlique, Thibault, He, Chenfei, Berglöf, Anna, Gupta, Dhanu, Saher, Osama, Daza Cruz, Miguel Ángel, Peña-Perez, Lucia, Yu, Liang, Zain, Rula, Karlsson, Mikael C. I., Månsson, Robert, Smith, C. I. Edvard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7284087/
https://ncbi.nlm.nih.gov/pubmed/32492159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001319
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller